Examination of Firearms Review: 2007 to 2010 - Interpol

167 Anita U, Lee HS, Kydd RR, Tingle MD, Russell BR. Pharmacokinetics of
‘party pill’ drug N-benzylpiperazine (BZP) in healthy human participants.
Forensic Science International 2009 Apr; 186 (1-3): 63-67.
168 Vorce SP, Holler JM, Levine B, Past MR. Detection of 1-benzylpiperazine
and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens
using GC-MS and LC-ESI-MS. Journal of Analytical Toxicology 2008
Jul-Aug; 32 (6): 444-450.
169 Westphal F, Junge T, Girreser U, Stobbe S, Pérez SB. Structure
elucidation of a new designer benzylpiperazine:
4-Bromo-2,5-dimethoxybenzylpiperazine. Forensic Science International
2009 May; 187 (1-3): 87-96.
170 EMCDDA action on new drugs briefing paper: Understanding the ‘Spice’
phenomenon (A report from an EMCDDA expert meeting 6 March 2009),
avaiable on line at
http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_EMCDD
A_Understanding%20the%20‘Spice’%20phenomenon_1Update%20200
90514.p. (Accessed Feb, 2010)
171 Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y. Chemical analysis of
synthetic cannabinoids as designer drugs in herbal products. Forensic
Science International 2010 May; 198 (1-3): 31-38.
172 Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y.
Identification of a cannabinoid analog as a new type of designer drug in a
herbal product. Chemical & Pharmaceutical Bulletin (Tokyo) 2009 Apr;
57(4): 439-441.
173 Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N.
'Spice' and other herbal blends: HarmLess incense or cannabinoid
designer drugs? Journal of Mass Spectrometry 2009 May; 44 (5):
832-837.
174 Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst
L, et al. Spice: A never ending story? Forensic Science International 2009
Oct; 191 (1-3): 58-63.
175 Mustata C, Torrens M, Pardo R, Pérez C, Psychonaut Web Mapping
Group, Farré M. Spice drugs: Cannabinoids as new designer drugs.
Adicciones 2009; 21(3): 181-186.
176 Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R,
Schulz K. Withdrawal phenomena and dependence syndrome after the
consumption of "Spice Gold". Deutsches Arzteblatt International 2009 Jul;
106 (27): 464-467.
177 Peters FT, Meyer MR, Theobald DS, Maurer HH. Identification of
cytochrome P450 enzymes involved in the metabolism of the new
designer drug 4'-methyl-alpha-pyrrolidinobutyrophenone. Drug
Metabolism and Disposition 2008 Jan; 36 (1): 163-168.
702